Heron Therapeutics has been buoyed by the news that its painkiller agent HTX-011 met all of its primary and secondary endpoints in Phase 3 studies investigating its efficacy in relieving pain and opioid use in patients undergoing bunionectomy and hernia repair, sending its shares soaring by up to 32%.
Reageer